For Forest, No Single Silver Bullet But Many Opportunities
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
There is no quick fix to guide Forest Laboratories through 2012, when its best seller, the antidepressant Lexapro, goes off patent. But management thinks it will have enough patches in place by then to compensate for lost revenues and avert disaster.
You may also be interested in...
Forest's Bystolic Gets Unanimous Thumbs-Down
Forest's beta blocker Bystolic suffered a resounding defeat when FDA's Cardio-Renal advisory committee unanimously recommended that the agency not approve it to treat chronic heart failure.
Good Showing For Nycomed's COPD Drug Daxas
Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.